Sobi's Doptelet Launch In EU To Drive Transformation
UK Is First EU Market For Commercial Launch
Sobi is launching the thrombocytopenia drug Doptelet in Europe after acquiring the originator, Dova Pharmaceuticals, and expects to capture significant market share from older products while adding to its business in rare diseases, hematology, and immunology.
You may also be interested in...
A Phase III trial of Swedish Orphan Biovitrum’s Doptelet in solid tumor cancer patients with chemotherapy-induced thrombocytopenia has failed. The setback could affect the firm’s growth expectations.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.